ARGENX SE (ARGX) Form 6-K — Oct 22, 2026
argenx reported Q3 2026 VYVGART product net sales of $1.7 billion, up 54% year-over-year and 13% quarter-over-quarter, with quarterly profit of $506 million and basic EPS of $8.07 versus $5.61 a year ago. The company ended the quarter with $3.7 billion in cash and current financial assets after paying roughly $2.1 billion, net of acquired cash, for its acquisition of Forte Biosciences, and now expects combined 2026 R&D and SG&A expenses of about $4 billion.
Key figures
- Eps
- 8.07
- Revenue
- 1721000000
- Guidance
- Combined R&D and SG&A expenses of approximately $4 billion for 2026, including Forte transaction-related costs.
- Net Income
- 506000000
- Revenue Yoy
- 54%
- Cash Position
- 3700000000
- Shares Outstanding
- 62735385
- Qoq growth
- 13%
- Diluted eps q3
- 7.8
- Operating margin
- 28%
- Basic eps q3 2025
- 5.61
- Operating profit q3
- $486 million
- Q3 product net sales
- $1.7 billion
- Forte acquisition cost
- ~$2.1 billion paid net of acquired cash
- Pdufa date pediatric gmg
- February 18, 2027
- Adjusted operating margin
- 37% excluding $150 million Forte acquisition-related expenses
- Q3 2025 product net sales
- $1.127 billion
- Nine month product net sales
- $4.534 billion
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.